Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of early chemotherapy on angiogenesis after laparoscopic resection in colorectal cancer patients

ABSTRACT: Interventions: Drug : Colorectal cancer patients treated with minimally invasive surgery followed by adjuvant FOLFOX chemotherapy were randomly assigned to two groups: the FOLFOX group, FOLFOX on postoperative day (POD) 7-9; the control group, FOLFOX on POD 21. FOLFOX4 chemotherapy: Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2; 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2; Oxaliplatin 85 mg/m2 iv d1 Blood sampling is performed preoperatively, and POD 3, POD 7-9, POD 9-11, POD 21. Primary outcome(s): levels of plasma VEGF, Ang-1, Ang-2, TSP-1 Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT

DISEASE(S): Neoplasms

PROVIDER: 2509659 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Pharmacogenomic study on colorectal cancer chemotherapy - modified FOLFOX6- (Oxaliplatin with infusional 5-FU/l-Leucovorin) and FOLFIRI (irinotecan with infusional 5-FU/l-Leucovorin)-based regimen-

Project description:Interventions: mFOLFOX6 (-BEV): On Day1, iv infusion of 85 mg/m2 of l-OHP and 175 mg/m2 of L-LV for 2hrs, followed by bolus infusion of 400 mg/m2 5-FU. Then, continuous infusion of 2400 mg/m2 5-FU for 46 hrs. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. mFOLFOX6 (+BEV): The first treatment after the surgery is subject to the mFOLFOX6 (-BEV) regimen. From the 2nd cycle, first infusion of 5 mg/kg BEV. Then follow the mFOLFOX6 (-BEV) regimen. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. mFOLFIRI(-BEV): On Day1, iv infusion of 150 mg/m2 of CPT-11 and 175 mg/m2 of L-LV for 2 hrs, followed by bolus infusion of 400 mg/m2 5-FU. Then, continuous infusion of 2400 mg/m2 5-FU for 46 hrs. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. mFOLFIRI (+BEV): The first treatment after the surgery is subject to the FOLFIRI (-BEV) regimen. From the 2nd cycle, first infusion of 5 mg/kg BEV. Then follow the FOLFIRI (-BEV) regimen. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. Primary outcome(s): Response rate (RECISTv1.1) Study Design: Parallel Randomized

| 2622327 | ecrin-mdr-crc

To study how safe and effective is Irinotecanin treatment of colorectal cancer patients.

Project description:Intervention1: Irinotecan injection: ?Irinotecan injection 180 mg/m2 IV over 90 min, on Day 1, Day 15, Day 29 of each cycle. Combination Drug: ?Leucovorin 200 mg/m2 IV over 2 hrs, on Day 1, Day 2, Day 15, Day 16, Day 29, and Day30 of each cycle. ?5-Fluoro Uracil bolus 400 mg/m2 IV bolus, on Day 1, Day 2, Day 15, Day 16, Day 29, and Day 30 of each cycle. ?5-Fluoro Uracil infusion 600 mg/m2 IV over 22 hrs, on Day1, Day 2, Day 15, Day 16, Day29, and Day 30 of each cycle. Control Intervention1: NIL: NIL Primary outcome(s): Overall Objective Response Rate (ORR) by RECIST criteria version 1.1Timepoint: Measured at baseline, before initiation of 3rd cycle (Day85), at the end of 6th cycle (Day240) and if required at the end of the study (1 year)

| 2572851 | ecrin-mdr-crc

JCOG2004: Randomized Phase II Study of Bevacizumab plus FOLFIRI versus Ramucirumab plus FOLFIRI versus Aflibercept plus FOLFIRI for Metastatic Colorectal Cancer after failure of First-line chemotherapy with Fluoropyrimidine and Oxaliplatin to Explore Predictive Biomarker

Project description:Interventions: Arm A: Bevacizumab+FOLFIRI (1) BEV 5 mg/kg iv (over 10 minutes) day 1 (2) l-LV 200 mg/m2 iv (2hr) day 1 (3) IRI 150 mg/m2 iv (90min) day 1 (4) 5-FU 400 mg/m2 bolus day 1 (5) 5-FU 2,400 mg/m2/46h continuous iv day 1-3 Arm B: Ramucirumab+FOLFIRI (1) RAM 8 mg/kg iv (1hr) day 1 (2) l-LV 200 mg/m2 iv (2hr) day 1 (3) IRI 150 mg/m2 iv (90min) day 1 (4) 5-FU 400 mg/m2 bolus day 1 (5) 5-FU 2,400 mg/m2/46h continuous iv day 1-3 Arm C: Aflibercept+FOLFIRI (1) AFL 4 mg/kg iv (1hr) day 1 (2) l-LV 200 mg/m2 iv (2hr) day 1 (3) IRI 150 mg/m2 iv (90min) day 1 (4) 5-FU 400 mg/m2 bolus day 1 (5) 5-FU 2,400 mg/m2/46h continuous iv day 1-3 Primary outcome(s): Progression-free survival Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2739106 | ecrin-mdr-crc

Phase 2 trial of FOLFIRI plus ziv-aflibercept in patients with colorectal cancer previously treated with oxaliplatin, fluoropyrimidins, bevacizumab, and trifluridine/tipiracil

Project description:Interventions: FOLFIRI plus ziv-aflibercept (Day 1) Ziv-aflibercept, 4 mg/kg, intravenously (IV) over 60 min (Day 1) Irinotecan, 150 mg/m2, IV over 90 min (Day 1) Leucovorin (l-LV), 200 mg/m2, IV over 120 min (Day 1) 5-FU, 400 mg/m2, bolus (Day 1-3) 5-FU, 2400 mg/m2, continuous infusion over 46 h Repeat the above every two weeks The dose of irinotecan can be reduced to 120 mg/m2 if patients are homozygous for UGT1A1*28 or UGT1A1*6, or heterozygous for both UGT1A1*28 and UGT1A1*6.;C480833,C533178;FOLFIRI, ziv-aflibercept Primary outcome(s): progression free survival Study Design: single arm study, open(masking not used), historical control, single assignment, treatment purpose

| 2614963 | ecrin-mdr-crc

A randomized controlled trial comparing resection of primary tumor plus chemotherapy with chemotherapy alone in incurable Stage IV colorectal cancer(JCOG1007, iPACS)

Project description:Interventions: A: Chemotherapy alone (mFOLFOX6 or CapeOX plus bevacizumab; mFOLFOX6: bevacizumab 5 mg/kg IV on day 1, l-leucovorin 200 mg/m2 and oxaliplatin 85 mg/m2 as a 2-hour IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 followed by 2,400 mg/m2 IV over 46 hours, repeated every 2 weeks; CapeOX: bevacizumab 7.5 mg/kg IV on day 1, l-leucovorin 130 mg/m2 on day 1 and Capecitabine 1000 mg/m2 per day orally from day 1 to day 14, repeated every 2 weeks) B: Primary resection followed by chemotherapy (mFOLFOX6 or CapeOX plus bevacizumab; mFOLFOX6: bevacizumab 5 mg/kg IV on day 1, l-leucovorin 200 mg/m2 and oxaliplatin 85 mg/m2 as a 2-hour IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 followed by 2,400 mg/m2 IV over 46 hours, repeated every 2 weeks; CapeOX: bevacizumab 7.5 mg/kg IV on day 1, l-leucovorin 130 mg/m2 on day 1 and Capecitabine 1000 mg/m2 per day orally from day 1 to day 14, repeated every 2 weeks) Primary outcome(s): Overall survival Study Design: Parallel Randomized

| 2623557 | ecrin-mdr-crc

An Exploratory Study for the Efficacy and Safety of Cetuximab in Combination with Irinotecan Re-challenge Versus Regorafenib in the Third-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer

Project description:Interventions: Experimental group:Cetuximab-targeted combination with irinotecan chemotherapy, the specific regimen is as follows: Cetuximab (trade name: Erbitux) once every two weeks, 500 mg/m2, d1; Irinotecan 180 mg/m2 ivgtt 90 min d1 q2w;Control group:Regorafenib oral treatment, the specific regimen is as follows: regorafenib 120 mg d1-21 q4w Primary outcome(s): Progression-free survival Study Design: Parallel

| 2687922 | ecrin-mdr-crc

Randomized phase II study of mFOLFOX6 versus TS-1/CPT-11 in patients with advanced/recurrent colorectal cancer

Project description:Interventions: Group A:mFOLFOX6 Day 1 day 2 day 14 L-OHP 2HR l-LV 200mg/m2 5-FU 2,400mg/m2 civ 2HR 46HR ------------- | 5-FU 400mg/m2 iv Rapid Group B:TS-1/CPT-11 CPT-11 80 mg/m2CPT-11 80 mg/m2 1.5 hours 1.5 hours TS-1 40-60 mg/m2 | | | | Day 1 day 15 day 21 day 35 One course takes 35 days (5 weeks). Primary outcome(s): Response Rate(RECIST) Study Design: Parallel Randomized

| 2616289 | ecrin-mdr-crc

A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Breast Cancer

Project description:This phase II study examined the pathological complete response (pCR) rate and safety of two gemcitabine-based combinations administered sequentially in breast cancer. We also examined gene expression profiles from tumor biopsies to identify biomarkers predictive of response. Methods: Indian women with large or locally advanced breast cancer received 4 cycles of gemcitabine 1200 mg/m2 plus doxorubicin 60 mg/m2 (Gem+Dox), then 4 cycles of gemcitabine 1000 mg/m2 plus cisplatin 70 mg/m2 (Gem+Cis), and surgery. To examine dynamic changes in molecular profiles after one dose of therapy, we used three alternate sequences during cycle 1 (Gem d1, 8; Dox d2; Gem d1, 8; Dox d1; or Gem d2, 8; Dox d1). Results: Of 65 women (median age 46) treated, 13 (24.5% of 53 patients with surgery) had a pCR and 22 (33.8%) had a complete clinical response. Patients who received Gem d1, 8 and Dox d2 in cycle 1 (20/65) reported more toxicities, with G3/4 neutropenic infection/febrile neutropenia (7/20) and vomiting (5/20) as the most common cycle 1 events. Four drug-related deaths occurred. 46/65 patients yielded successful pretreatment gene expression profiles. Ten-fold cross-validated supervised analyses identified gene expression patterns that predicted with >73% accuracy (1) clinical complete response after eight cycles, (2) overall clinical complete response, and (3) pCR. Conclusions: This neoadjuvant regimen showed strong activity. A subset of patients receiving Gem d1, 8 and Dox d2 experienced unacceptable toxicity, whereas patients on other sequences had more manageable safety profiles. The predictive gene expression patterns may provide a method for selecting patients most likely to benefit from gemcitabine-containing neoadjuvant therapy. Key words: breast cancer, chemotherapy, gemcitabine, , gene expression, microarrays, neoadjuvant therapy Keywords: Dose response

2008-01-12 | GSE8465 | GEO

Efficacy exploration of 2nd line in advanced colorectal cancer

Project description:Interventions: Drug : Registry study Day 1. Aflibercept + FOLFIRI • aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus) • Leucovorin: 400 mg/m2 IV infusion for over 2 hours • Irinotecan: 150 mg/m2 IV infusion for over 1 hours • 5-FU: 400 mg/m2 IV bolus injection for over 5 minute • 5-FU: 2400 mg/m2IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity 17 potential protein biomarkers, including cytokines and angiogenic factors, is chosen for analysis based on their roles in tumor progression: HGF, PIGF, VEGF-A, VEGF-C, VEGF-D, INF-r, IL-6, IL-8, Angiopoietin-2, sNeuropillin-1, TSP-2, OPN, sVEGFR1,2,3, sICAM-1, sVCAM-1, and TIMP-1 - Plasma is collected at baseline (Cycle 1) and cycle 4 - Plasma levels of the potential biomarkers are determined by enzyme-linked immunosorbent assays Primary outcome(s): Profression free survival

| 2512693 | ecrin-mdr-crc

Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC

Project description:Trial design: * Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. * Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve. * Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria, Poland, Serbia, Russia, Ukraine and the United Kingdom). * Dosing regimen: * Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan and HA-Irinotecan dose in must be reduced to 150 mg/m2). * Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan. * 5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion. * Repeat every 2 weeks for 8 months. * Patient accrual over approximately 12-14 months. * Monitoring to 18 months post-randomization. * 390 patients. * Progression Free Survival (PFS) primary endpoint. * Safety analysis on the initial 20 patients.

| 2101890 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data